| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

3 June 2024

ORYZON announces journal publication of final Phase IIa ALICE results with iadademstat in The Lancet Haematology

17-20 June 2024

European Network to Cure ALS (ENCALS) 2024

Karolinska Institutet

Stockholm

Sweden

13-16 June 2024

European Hematology Association (EHA) 2024

IFEMA Recinto Ferial

Madrid

Spain

3-6 June 2024

BIO International Convention 2024

San Diego Convention Center, San Diego

CA

United States

30 May 2024

ORYZON to provide corporate progress updates at several events in June

29 May 2024

ORYZON selected as Associated Partner in the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)

28 June 2024

Annual General Shareholders’ Meeting 2024

Madrid

Spain

28-30 May 2024

Foro Medcap BME 2024

Madrid Stock Exchange Palace

Madrid

Spain

16 May 2024

RSC Hot Topics: Covalent Drug Discovery 2024

15 May 2024

Asebio Investor Day 2024

Kursaal Elkargunea Center, San Sebastián

Guipúzcoa

Spain

Pagination

First page «
Previous page ‹
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel